| Primary | Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score | Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. MADRS is 10-item instrument measuring depression; scale 0(Normal) and 6(most abnormal). Total possible score is 0 - 60. | Intent to treat (ITT) population observed cases | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| | | Title | Denominators | Categories |
|---|
| Week 1 (n=161, 153, 159) | | | Title | Measurements |
|---|
| - OG000-6.07± 0.62
- OG001-7.66± 0.73
- OG002-5.75± 0.65
|
| | Week 2 (n=135, 142, 146) |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | Mixed Models Analysis | Fixed categorical: treatment, rapid cycling, center, visit, prior hosp & treatment-by-visit interaction & fixed continuous effect of baseline value | 0.6409 | Hochberg's adjustment was used for multiple comparisons adjustment | | | | | | | | | | | | | Superiority or Other (legacy) | | | |
|
| Secondary | Response Greater Than or Equal to 50 Percent Decrease From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score | Participants with MADRS Total Score greater or equal to 50 percent decrease from baseline responded yes; others responded no. Endpoint is last observation carried forward (LOCF) among Week 1 - Week 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6 (most abnormal). Total possible score is 0 - 60 | Intent to treat (ITT) population observed cases. Not all subjects answered at each Week | Posted | | Number | | Participants | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Response Greater Than or Equal to 50 Percent Decrease From Baseline in Hamilton Depression Rating Scale (HAM-D 17) Total Score | Participants with greater than or equal to 50 percent decrease from baseline in HAMD-17 total score responded yes; others responded no. Endpoint is LOCF endpoint among Week 1 - 6; Total score is first 17 items of HAM-D 25: measures range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52. | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6 Not all subjects answered each Week. | Posted | | Number | | participants | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Global Assessment of Functioning (GAF)at Endpoint, Last Observation Carried Forward (LOCF) | Change is observed value at endpoint minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 - 6; GAF is used to assess global psychological, social, & occupational functioning; 100=normal and 0=greatest abnormality | Intent to treat (ITT) population observed cases, Last Observation Carried Forward (LOCF). | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline, 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Remission as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than or Equal to 12 | Response was Yes if MADRS Total Score was less than, equal to 12, if not, response was no. Endpoint is LOCF endpoint among Week 1 through 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6(most abnormal) | ITT Observed Cases.Endpoint is LOCF endpoint among Week 1 through Week 6; Not all subjects answered each week. | Posted | | Number | | participants | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Remission as Measured by Hamilton Depression (HAM-D 17) Total Score Less Than or Equal to 7 | Response was yes when HAM-D 17 total score was less than or equal to 7 , if not, response was no. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25,which measures the range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52. | ITT Observed Cases.Endpoint is LOCF endpoint among Week 1 through Week 6 Not all subjects answered each week. | Posted | | Number | | Participants | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Hamilton Depression (HAM-D 17) Total Score | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25, which measures the range of depressive symptoms patient currently experiencing; scale 0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme. Total possible score 0 - 52. | ITT Population Observed Cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Hamilton Anxiety Rating (HAM-A) | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. HAM-A is a 14-item scale: rates intensity of psychic anxiety and somatic anxiety on a 5-point severity scale (range: 0=not present to 4=very severe). Total possible score is 0 - 56. | ITT population Observed Cases. Endpoint is LOCF endpoint among Week 1 through Week 6 | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Total Score of Young Mania Rating Scale (YMRS) | Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. YMRS: 11 item instrument with scale 0 to 4 for 7 items and 0 to 8 for 4 items; 0=normal; 4 or 8=most abnormal. Total possible score is 0 - 60. | | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Assessment of Global Clinical Severity of Symptoms (CGI-S) | Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-S measures severity of patient's mental illness. Scale range: 0 = not assessed, 1 = normal, 7 = among most extremely ill | ITT population Observed Cases | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Global Clinical Improvement of Symptoms (CGI -I) | Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-I is an instrument for Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse | ITT population Observed Cases | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Total Score in Hamilton Depression (HAM-D 25) | Change: observed value at each visit minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 through Week 6. HAM-D 25: measures the range of depressive symptoms experienced. 25 Items with Scale range:0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme.Total possible score is 0 - 72. | ITT Population Observed Cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 Weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Response as Measured by CGI-I Score Less Than or Equal to 2 | Response each week was yes if CGI-I score less than or equal to 2 (much or very much improved), if not, response was no; Endpoint is LOCF endpoint among Week 1 through Week 6. CGI-I is a Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse | ITT Population Observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. Not all subjects answered each week. | Posted | | Number | | Participants | | Week 1 through Week 6 (endpoint) | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Sheehan Disability Scale (SDS) Total Score at Endpoint | Observed value each visit minus baseline value. Endpoint is LOCF Week 1 through Week 6. SDS: patient rated measure of disability and impairment in 3 items: work/school, social life, family life/home responsibilities:0(no disruption)- 10(extreme disruption). Total possible is 30. | ITT Population Observed cases. Endpoint is LOCF endpoint among Week 1 - 6; n= 128, 126, 128; number of subjects who responded to the scale. | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to Week 6 | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Total Score at Endpoint | Change is observed value at each visit minus baseline value. LOCF endpoint among Week 1 through Week 6. Q-LES-Q: 16-item instrument for patients assessment of his/her quality of life; overall level of satisfaction scale 1=very poor to 5=Very good (1 item re medication can be blank). Total possible score 15 - 80 | ITT Population Observed Cases.n= 142, 137, 139; number of subjects who responded to the scale. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 Weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Bech Melancholia Score | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Bech Melancholia is the sum of Scores on 6 Items pertaining to melancholia within Hamilton Depression Rating Scale (HAM-D). Scale 0 to 4, higher scores reflecting greater severity;Total possible 0 - 24. | ITT Population Observed cases | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 Weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Anxiety/Somatizations Factor Total Score | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores on 6 Items measuring anxiety/somatization within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4, higher scores reflecting greater severity. Total possible 0 - 24. | ITT Population Observed Cases | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 Weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Retardation Factor Scores | Change is observed value at each visit minus baseline value. This instrument = sum of Scores of 4 items on retardation within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 16. | | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 Weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Sleep Disturbance Factor Score | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores of 3 items on sleep disturbance within Hamilton Depression Rating Scale (HAM-D). Scale range 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 12. | ITT Population Observed cases | Posted | | Least Squares Mean | Standard Error | score on scale | | Baseline to 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Verbal Memory Trial Performance Total Score at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is part of Brief Assessment of Cognition and measures recall of 15 words repeated 5 times. Range 0-75 words, higher number reflects better recall. | Intent to Treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | words | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test Immediate Recall List 1 Emotional Words at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition measuring immediate recall of 15 emotional words; higher number of words is better recall. | Intent to treat (ITT) population observed cases | Posted | | Least Squares Mean | Standard Error | words | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test Immediate Recall Non-Emotional Words List 1 at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument measures immediate recall of 15 non-emotional words (List 1); higher number of words is better recall. | Intent to treat (ITT) population observed cases | Posted | | Least Squares Mean | Standard Error | words | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test, Immediate Recall, List 2 Emotional Words at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is in Brief Assessment of Cognition and measures immediate recall of 15 emotional words (List 2); higher number of words is better recall | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | words | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test, Immediate Recall, List 2 Non-Emotional Words at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 2); higher number of words is better recall | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | words | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test, Immediate Recall, List 3 Emotional Words at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 emotional words (List 3); higher number of words is better recall | Intent to treat (ITT) population observed cases.Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | words | | Baseline to Week 6 LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test, Immediate Recall, List 3 Non-Emotional Words at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 3); higher number of words is better recall | Intent to treat (ITT) population observed cases | Posted | | Least Squares Mean | Standard Error | words | | Baseline to Week 6 LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test, Immediate Recall, Cued-Recall Non-Emotional Words at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 non-emotional words; higher number of words is better recall | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | words | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test, Immediate Recall, Cued-Recall Emotional Words at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 emotional words; higher number of words is better recall | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | words | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Digit Sequencing Task at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which patient sequences digits from lowest to highest. Range of number of correct responses (0-28); higher numbers show better digit sequencing and greater cognition. | Intent to treat (ITT) population observed cases | Posted | | Least Squares Mean | Standard Error | Number Correct | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Token Motor Task at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which a patient places as many of 100 tokens (2 at a time) into a container as they can within 60 seconds. The higher number of tokens placed = patient is better at motor tasks | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | Number of Tokens | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Verbal Fluency in Naming Categories at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition.Patients are given 60 seconds to name as many words as possible within a given category. The more words named=better cognition. | Intent to treat (ITT) population observed cases.Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | Number Correct | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Verbal Fluency Controlled Word Association at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. Patients given 60 seconds to generate as many words as possible that begin with a given letter; better verbal fluency = more words | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | Number Correct | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Symbol Coding at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. For 90 seconds, Patient writes numerals 1-9 as matched to symbols. Range 0 to 110 with higher totals = better cognition. | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | Total Correct | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Tower of London Test at Endpoint | Change is observed value at each visit minus baseline value. Endpoint: LOCF endpoint among Week 1 through Week 6. Brief Assessment of Cognition: subjects asked to arrange balls in 2 pictures so they are identical and give the total number of ball movements to reach this arrangment. Range: 0-22; more correct = better cognition. | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | Number Correct | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test, Delayed Recognition, Emotional Words at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition in which the number of correct emotional words in delayed recognition is measured. Range 0-75 with higher numbers showing better cognition. | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6 | Posted | | Least Squares Mean | Standard Error | Words | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test, Delayed Recognition, Emotional Words False Alarms at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition which measures number of correct emotional word's false alarms (during delayed recognition). Higher number = better cognition | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | Number Correct | | Baseline to 6 Weeks LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of Non-Emotional Words (Delayed Recognition); higher number of words = better cognition | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | Number Correct | | Baseline to Week 6 LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |
| Secondary | Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words False Alarms at Endpoint | Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of correct non-eEmotional word's false alarms(at delayed recognition). Higher number of words = greater cognition | Intent to treat (ITT) population observed cases. Endpoint is LOCF endpoint among Week 1 through Week 6. | Posted | | Least Squares Mean | Standard Error | Number Correct | | Baseline to Week 6 LOCF | | | | ID | Title | Description |
|---|
| OG000 | 120-160mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 60-80 milligram (mg) BID (twice a day) | | OG001 | 40-80 mg Ziprasidone | Subjects were assigned to a ziprasidone fixed-flexible dosing arm: 20-40 milligram (mg) twice a day (BID) | | OG002 | Placebo | Subjects were assigned to placebo |
| |